PanGenex releases statement on Omega-3 and Lipideme

PanGenex Corporation (Pink Sheets: PGCX) ("PanGenex" or "the Company") a global manufacturer and distributor of nutraceutical and dietary supplement products, today released a statement in response to the many inquiries about Omega-3 and Lipideme.

Dr. Ronald Caputo, a PanGenex Board Member and one of America's leading Interventional Cardiologists, stated, "The benefits of Omega-3 fatty acids have been well established through multiple extensive clinical studies. They have been demonstrated to lower the risk of sudden cardiac death and improve blood lipid profiles. Omega-3 fatty acids are also safe and well tolerated without serious side effects. As such, they are well accepted by both the medical community and the general public. What is not generally appreciated is that not all Omega-3 supplements provide equivalent benefit. There are major differences between products in regard to purity and formulation.

There are several unique features of Lipideme that make it superior to other Omega-3 products. Firstly, it provides an extremely high level of pure and well balanced Omega-3 fatty acids, far surpassing any other commercially available "fish oil" supplement of which I am aware. This is incredibly important in order to avoid the unnecessary and detrimental heavy metals and non-Omega-3 fats found in other products. Secondly, this proprietary formulation also incorporates the other well established natural lipid lowering agents phytosterols and tocotrienols - the natural "statins". Thirdly, the inclusion of Co-enzyme Q adds an important anti-oxidant component to the compound.

As a high volume Interventional Cardiologist I am well acquainted with the results of untreated lipid abnormalities. I literally see blockages in coronary arteries every day. Lipideme provides an excellent option in the battle against coronary artery disease and I have seen significant clinical benefit in many patients from its use." Dr. Caputo concluded.

SOURCE PanGenex Corporation